and dividend income 16 16 37 127% 128% Other income 59 129 81 37% -37% Selling and administrative expenses (1,660) (2,148) (1,721) 4% -20% Exploration and evaluation expense (9) (15) (4) -50% -70% Gain
19% 5,227 -25% 9,158 6,106 50% EBITDA -120 88 -236% 345 -135% 225 229 -2% อัตรากำไร EBITDA (%) -3.1% 2.7% -5.8% 6.6% -9.7% 2.5% 3.8% -1.3% Stock Gain/(Loss) & NRV -374 -58 545% 92 -507% -282 -132 114
invoice โดยเปรียบเทียบราคา / เงื่อนไขการชำระเงินว่าต่างจากที่ทำกับลูกค้าทั่วไป / ข้อมูลอุตสาหกรรมหรือไม่ ทั้งนี้ ราคาและเงื่อนไขที่นำมาใช้อ้างอิงต้องมีขนาดและปริมาณของรายการที่มากเพียงพอ จึงจะเป็นราคาและ
majority of other incomes came from bad debt recovery of 500 million baht and gain on sales of written-off accounts receivable of 346 million baht. Moreover, the income for the fiscal year 2016 of company’s
deposits received from customers of 3,845 Million Baht, deferred tax liability on gain from JV transaction of 2,205 Million Baht. Total interest bearing debts equaled to 20,336 Million Baht. Shareholders
Baht, debentures (net) of 1,805 Million Baht and advances and deposits received from customers of 3,845 Million Baht, deferred tax liability on gain from JV transaction of 1,856 Million Baht. Total
be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the
2017 compared to Q4 2016: Q4 2017 Q4 2016 YoY change YoY % change Unit: Million Thai Baht (THB) Sales and service income 209.13 181.21 27.92 15% Gain from exchange rate 0.44 0.57 -0.13 -23% Other income
which mainly due to commission income increased Baht 0.3 million and increased gain on exchange rate at Baht 0.1 million. For this year, as said, the gain on exchange rate at Baht 0.1 million while prior